Literature DB >> 17433904

Quality assurance issues and interpretation of assays.

Ian Mackie1, Peter Cooper, Steve Kitchen.   

Abstract

The consequences of an erroneous thrombophilia diagnosis may be serious if it is used to determine clinical management. Therefore careful selection, assessment, and control of laboratory tests for thrombophilia are essential. As for other coagulation tests, the pre-analytical phase must be carefully controlled with attention to the specific problems associated with each type of assay. The investigator must then recognize that for most laboratory tests of thrombophilia, there are a number of assay types available, often based on different principles of analysis. This creates the potential for different users to obtain varying results depending on the technique employed. Such problems can occur in assays of antithrombin activity, depending on whether the assay employs factor Xa, human thrombin, or bovine thrombin. In clot-based assays of protein C and protein S, there can be specificity problems related to interference by factor V Leiden (FVL), antiphospholipid antibodies, and other substances. Even genetic tests can give erroneous results and should not automatically be seen as absolute without supporting evidence and careful quality-control measures. Whatever technique is selected, it is mandatory to incorporate sufficient concurrent quality-control samples to validate the results of thrombophilia tests. These should include assessment of the parameter at normal and abnormal levels to give confidence in results across the measurement range that would normally be encountered in routine practice. This should be used in conjunction with regular participation in external quality assessment (EQA) (which has been linked to improved laboratory performance in thrombophilia testing). Larger EQA programs can provide information concerning the relative performance of analytical procedures, including the method principle, reagents, and instruments. Herein, we describe many of the methodologic effects in detail. We use specific examples to illustrate the general principle that, in performing laboratory testing for thrombophilia, one must always consider the performance characteristics and limitations of the assay in use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433904     DOI: 10.1053/j.seminhematol.2007.01.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  1 in total

1.  Thrombophilia testing in the inpatient setting: impact of an educational intervention.

Authors:  Henry Kwang; Eric Mou; Ilana Richman; Andre Kumar; Caroline Berube; Rajani Kaimal; Neera Ahuja; Stephanie Harman; Tyler Johnson; Neil Shah; Ronald Witteles; Robert Harrington; Lisa Shieh; Jason Hom
Journal:  BMC Med Inform Decis Mak       Date:  2019-08-20       Impact factor: 2.796

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.